ArticleDie Naturwissenschaften2026
Promoting mechanisms of papillary thyroid carcinoma by the LncRNA CASC2/miR-193a-3p/RBM24 axis.
Article in Die Naturwissenschaften, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Papillary thyroid carcinoma (PTC), the most common thyroid malignancy, is characterized by a high incidence rate and unfavorable outcomes. The competing endogenous RNA (ceRNA) network is systemic and intricate, incorporating various non-coding RNAs, and offers new insights into the cancer pathogenesis. This study explored ceRNA-mediated pathways contributing to PTC pathogenesis. Datasets from GEO were analyzed to detect differentially expressed mRNAs (DEmRNAs) and lncRNAs (DElncRNAs) in PTC, which identified 49 DElncRNAs and two key genes, RBM24 and LIPI. Then a total of 119 shared microRNAs (miRNAs) of them were predicted, leading to the construction of a comprehensive ceRNA regulatory network. Among these, lncRNA CASC2/miR-193a-3p/RBM24 was identified as the core regulatory axis, by using the cytoHubba plugin in Cytoscape. Expression analysis using public datasets and clinical tissue samples revealed significant downregulation of CASC2 and RBM24, alongside upregulation of miR-193a-3p in PTC. Dual-luciferase assays verified CASC2-miR-193a-3p and miR-193a-3p-RBM24 binding. In IHH4 cells, CASC2 knockdown promoted proliferation, migration, and invasion, whereas miR-193a-3p inhibition partly reversed the effects. The RBM24 effect experiments demonstrated that reduced RBM24 facilitated IHH4 progression. Xenograft models validated the expression patterns of CASC2, miR-193a-3p, and RBM24 in vivo, showing that CASC2 knockdown promoted tumor growth. This study is the first to identifies lncRNA CASC2/miR-193a-3p/RBM24 as a critical modulator of PTC progression. By influencing proliferation, apoptosis, and motility, this axis sheds light on the molecular mechanisms of PTC and highlights the targets for therapeutic intervention.
Indexed as
Identifiers
41729285What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.